Cowen and Company restated their buy rating on shares of Urogen Pharma (NASDAQ:URGN) in a research note published on Wednesday.

“URGN presented updates for MitoGel’s Phase 3 OLYMPUS trial (topline data in 2Q18).”,” the firm’s analyst commented.

A number of other research firms have also commented on URGN. CIBC reaffirmed an outperform rating and issued a $51.00 price objective (up from $32.00) on shares of Urogen Pharma in a research note on Wednesday. Raymond James Financial, Inc. lowered Urogen Pharma from an outperform rating to a market perform rating in a research note on Wednesday. UBS AG lowered Urogen Pharma from an outperform rating to a market perform rating in a research note on Wednesday. Oppenheimer Holdings, Inc. set a $51.00 price objective on Urogen Pharma and gave the stock an outperform rating in a research note on Tuesday. Finally, Zacks Investment Research lowered Urogen Pharma from a hold rating to a sell rating in a research note on Thursday, September 14th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $36.80.

Urogen Pharma (NASDAQ:URGN) traded up $0.75 during trading on Wednesday, hitting $41.00. The company had a trading volume of 176,311 shares, compared to its average volume of 99,011. Urogen Pharma has a one year low of $13.01 and a one year high of $44.63.

COPYRIGHT VIOLATION WARNING: “Urogen Pharma (URGN) Earns Buy Rating from Cowen and Company” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/11/18/urogen-pharma-urgn-earns-buy-rating-from-cowen-and-company.html.

A number of institutional investors and hedge funds have recently modified their holdings of URGN. Spark Investment Management LLC acquired a new position in Urogen Pharma in the second quarter valued at approximately $856,000. Menora Mivtachim Holdings LTD. acquired a new position in Urogen Pharma in the second quarter valued at approximately $2,331,000. LLBH Private Wealth Management LLC acquired a new position in Urogen Pharma in the second quarter valued at approximately $695,000. Alps Advisors Inc. acquired a new position in Urogen Pharma in the second quarter valued at approximately $195,000. Finally, Jennison Associates LLC acquired a new position in Urogen Pharma in the second quarter valued at approximately $3,168,000. 40.55% of the stock is currently owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.